Is a vaccines needed against Candida albicans?

Medical Mycology

Volumn 43, Issue 2, 2005, Pages 97-115

  Mochon, A Brian ^a,b   Cutler, Jim E ^a,b  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Candida albicans; Immunoprevention; Prophylaxis; Vaccine

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; BETA 1,2 OLIGOMANNOSIDE VACCINE; CANDIDA ALBICANS VACCINE; CYCLOPHOSPHAMIDE; FLUCONAZOLE; FUNGUS VACCINE; HEAT SHOCK PROTEIN 90 VACCINE; KILLER TOXIN VACCINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY KT4; MYCOGRAB; P43 VACCINE; PYRROLE DERIVATIVE; RECOMBINANT ANTIBODY; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ANTIFUNGAL ACTIVITY; CANDIDA ALBICANS; CANDIDIASIS; CELLULAR IMMUNITY; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; HUMAN; IMMUNE SYSTEM; IMMUNOPROPHYLAXIS; IMMUNOTHERAPY; INCIDENCE; MUCOCUTANEOUS CANDIDIASIS; NONHUMAN; PATHOPHYSIOLOGY; PREVALENCE; REVIEW; T LYMPHOCYTE; VACCINATION; HEALTH SERVICE; IMMUNOLOGY;

CANDIDA; CANDIDA ALBICANS;

CANDIDA ALBICANS; CANDIDIASIS; FUNGAL VACCINES; HEALTH SERVICES NEEDS AND DEMAND; HUMANS;

EID: 15944365827     PISSN: 13693786     EISSN: None     Source Type: Journal    
DOI: 10.1080/13693780500035979     Document Type: Review

References (153)

1. Dobias B. Specific and nonspecific immunity in Candida infections. Acta Medica Scand 1964; 176(Suppl. 421): 5-79.
2. Segal E. Vaccines against fungal infections. Crit Rev Microbiol 1987; 14: 229-271.
3. Polonelli L, Poulain D, Cole GT, et al. New strategies in vaccination against fungal infection. J Med Vet Mycol 1994; 32(Suppl. 1): 105-112.
4. Deepe GS Jr. Prospects for the development of fungal vaccines. Clin Microbiol Rev 1997; 10: 585-596.
5. Dixon DM, Casadevall A, Klein B, et al. Development of vaccines and their use in the prevention of fungal infections. Med Mycol 1998; 36(Suppl. 1): 57-67.
6. Cassone A, De Bernardis F, Ausiello CM, et al. Immunogenic and protective Candida albicans constituents. Res Immunol 1998; 149: 289-299.
7. Lopez-Ribot JL, Casanova JL, Murgui A, et al. Antibody response to Candida albicans cell wall antigens. FEMS Immunol Med Microbiol 2004; 41: 187-196.
8. Saarela HJ, Jousimies-Somer H, Takala A, et al. Age-related acquisition of oral and nasopharyngeal yeast species and stability of colonization in young children. Oral Microbiol Immunol 1999; 14: 176-182.
9. Cohen R, Roth FJ, Delgado E, et al. Fungal flora of the normal human small and large intestine. N Engl J Med 1969; 280 638-641.
10. Boschman CR, Bodnar UR, Tornatore MA, et al. Thirteen-year evolution of azole resistance in yeast isolates and prevalence of resistant strains carried by cancer patients at a large medical center. Antimicrob Agents Chemother 1998; 42: 734-738.
11. Milan EP, Burattini MN, Kallas EG, et al. Azole resistance among oral Candida species isolates from AIDS patients under ketoconazole exposure. Diagn Microbiol Infect Dis 1998; 32 211-216.
12. Beck-Sague C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J Infect Dis 1993; 167: 1247-1251.
13. Pfaller MA, Jones RN, Messer SA, et al. National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. Diagn Microbiol Infect Dis 1998; 30: 121-129.
14. Pfaller MA, Jones RN, Doern GV, et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. J Clin Microbiol 1998; 36: 1886-1889.
15. Sullivan D, Haynes K, Bille J, et al. Widespread geographic distribution of oral Candida dubliniensis strains in human immunodeficiency virus-infected individuals. J Clin Microbiol 1997; 35: 960-964.
16. Odds FC. Candida and Candidosis. London: Bailliere Tindall, 1988.
17. Lo H-J, Kohler JR, DiDomenico B, et al. Nonfilamentous C. albicans mutants are avirulent. Cell 1997; 90: 939-949.
18. Mitchell A. Dimorphism and virulence in Candida albicans. Curr Opin Microbiol 1998; 1: 687-692.
19. Cutler JE. Putative virulence factors of Candida albicans. Ann Rev Microbiol 1991; 45: 187-218.
20. Fidel PL Jr, Vazquez JA, Sobel JD. Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol Rev 1999; 12: 80-96.
21. Cole GT, Halawa AA, Anaissie EJ. The role of the gastro-intestinal tract in hematogenous candidiasis: from the laboratory to the bedside. Clin Infect Dis 1996; 22(Suppl. 2): S73-S88.
22. Bodey GP. Infection in cancer patients. A continuing association. Am J Med 1986; 81: 11-26.
23. Aronson IK, Soltani K. Chronic mucocutaneous candidosis: a review. Mycopathologia 1976; 60: 17-25.
24. Dreizen S. Oral candidiasis. Am J Med 1984; 30: 28-33.
25. Foxman B, Barlow R, D'arcy H, et al. Candida vaginitis self-reported incidence and associated costs. Sex Transm Dis 2000; 27: 230-235.
26. Kirkpatrick CH, Rich RR, Bennett JE. Chronic mucocutaneous candidiasis: model-building in cellular immunity. Ann Intern Med 1971; 74: 955-978.
27. Buckley RH, Lucas ZJ, Hattler BG, et al. Defective cellular immunity associated with chronic mucocutaneous monilias and recurrent staphylococcal botryomycosis: immunological reconstitution by allogeneic bone marrow. Clin Exp Immunol 1968; 3: 153-169.
28. Hoh MC, Lin HP, Chan LL, et al. Successful allogeneic bone marrow transplantation in severe chronic mucocutaneous candidiasis syndrome. Bone Marrow Transplant 1996; 18: 797-800.
29. Cutler JE. Acute systemic candidiasis in normal and congenitally thymic-deficient (nude) mice. J Reticuloendothel Soc 1976; 19: 121-124.
30. Jones-Carson J, Vazquez-Torres A, Warner T, et al. Disparate requirements for T cells in resistance to mucosal and acute systemic candidiasis. Infect Immun 2000; 68: 2363-2365.
31. Tebeta H, Mikami Y, Abe F, et al. Studies on defense mechanisms against Candida albicans infection in congenitally athymic nude (nu/nu) mice. Mycopathologia 1983; 84: 107-113.
32. Sobel JD. Pathogenesis and treatment of recurrent vulvovaginal candidiasis. Clin Infect Dis 1992; 14(Suppl. 1): S148-S153.
33. Romani L, Cenci E, Menacci A, et al. T helper cell dichotomy to Candida albicans: implications for pathology, therapy, and vaccine design. Immunol Res 1995; 14: 148-162.
34. Bistoni F, Cenci E, Menacci A, et al. Mucosal and systemic T helper cell function after intragastric colonization of adult mice with Candida albicans. J Infect Dis 2004; 168: 1449-1457.
35. Rogers TJ, Balish E, Manning DD. The role of thymus-dependent cell-mediated immunity in resistance to experimental disseminated candidiasis. J Reticuloendothel Soc 1976; 20: 291-298.
36. + lymphocytes reduce the severity of tissue lesions in murine systemic candidiasis, and CD4+ cells also demonstrate strain-specific immunopathological effects. Microbiology 1999; 145: 1631-1640.
37. Martino P, Girmenia C, Venditti M, et al. Candida colonization and systemic infection in neutropenic patients. Cancer 1989; 64: 2030-2034.
38. Nasser RM, Melgar GR, Longworth DL, et al. Incidence and risk of developing fungal prosthetic valve endocarditis after nosocomial candidemia. Am J Med 1997; 103: 25-32.
39. Bross J, Talbot GH, Maislin G, et al. Risk factors for nosocomial candidemia: a case-control study in adults without leukemia. Am J Med 1989; 87: 614-620.
40. Wey SB, Mori M, Pfaller MA, et al. Risk factors for hospital-acquired candidemia. Arch Intern Med 1989; 149: 2349-2353.
41. MacDonald L, Baker C, Chenoweth C. Risk factors for candidemia in a children's hospital. Clin Infect Dis 1998; 26 642-645.
42. Hilleman MR. Overview of the needs and realities for developing new and improved vaccines in the 21st century. Intervirology 2002; 45: 199-211.
43. Milstein J, Lambert S. Emergency response vaccines - a challenge for the public sector and the vaccine industry. Vaccine 2002; 21: 146-154.
44. Richards C, Emori TG, Edwards J, et al. Characteristics of hospitals and infection control professionals participating in the National Nosocomial Infections Surveillance System 1999. Am J Infect Control 2001; 29: 400-403.
45. Jarvis WR, Martone WJ. Predominant pathogens in hospital infections. J Antimicrob Chemother 1992; 29(Suppl. A): 19-24.
46. Richards MJ, Edwards JR, Culver DH, et al. Nosocomial infections in coronary care units in the United States. Am J Cardiol 1998; 82: 789-793.
47. Richards MJ, Edwards JR, Culver DH, et al. Nosocomial infections in medical intensive care units in the United States. Crit Care Med 1999; 27: 887-892.
48. Richards MJ, Edwards JR, Culver DH, et al. Nosocomial infections in pediatric intensive care units in the United States. Pediatrics 2004; 103: 1-7.
49. Lundstrom T, Sobel J. Nosocomial candiduria: a review. Clin Infect Dis 2001; 32: 1602-1607.
50. Karlowsky JA, Zhanel GG, Klym KA, et al. Candidemia in a Canadian tertiary care hospital from 1997 to 1996. Diagn Microbiol Infect Dis 1997; 29: 5-9.
51. Akpan A, Morgan R. Oral candidiasis. Postgrad Med J 2002; 78: 455-459.
52. Sangeorzan JA, Bradley SF, He X, et al. Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med 1994; 97: 339-346.
53. Giraldo P, Von Nowaskonski A, Gomes FAM, et al. Vaginal colonization by Candida in asymptomatic women with and without a history of recurrent vulvovaginal candidiasis. Obstet and Gynecol 2000; 95: 413-416.
54. Bauters TG, Dhont MA, Temmerman MI, et al. Prevalence of vulvovaginal candidiasis and susceptibility to fluconazole in women. Am J Obstet Gynecol 2002; 187: 569-574.
55. Ohmit SE, Sobel JD, Schuman P, et al. Longitudinal study of mucosal Candida species colonization and candidiasis among human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis 2003; 188: 118-127.
56. Lopez-Berestein G, Bodey GP, Fainstein V, et al. Treatment of systemic fungal infections with liposomal amphotericin B. Arch Intern Med 1989; 149: 2533-2536.
57. Ruhnke M, Schmidt-Westhausen A, Trautmann M. In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection. Antimicrob Agents Chemother 1997; 41: 575-577.
58. Sanati H, Belanger P, Fratti R, et al. A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei. Antimicrob Agents Chemother 1997; 41: 2492-2496.
59. Hazen KC, Baron EJ, Colombo AL, et al. Comparison of the susceptibilities of Candida spp. to fluconazole and voriconazole in a 4-year global evaluation using disk diffusion. J Clin Microbiol 2003; 41: 5623-5632.
60. Naider F, Shenbagamurthi P, Steinfeld AS, et al. Synthesis and biological activity of tripeptidyl polyoxins as antifungal agents. Antimicrob Agents Chemother 1983; 24: 787-796.
61. Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362: 1142-1151.
62. Odds FC. Resistance of yeasts to azole-derivative antifungals. J Antimicrob Chemother 1993; 31: 463-471.
63. Johnson EM, Warnock DW. Azole drug resistance in yeasts. J Antimicrob Chemother 1995; 36: 751-755.
64. Meunier F, Aoun M, Bitar N. Candidemia in immunocompromised hosts. Clin Infect Dis 1992; 14(Suppl. 1): S120-S125.
65. White DJ, Habib AR, Vanthuyne A, et al. Combined topical flucytosine and amphotericin B for refractory vaginal Candida glabrata infections. Sex Transm Dis 2001; 77: 212-213.
66. Shann J, Wilson J. Treatment of Candida glabrata using topical amphotericin B and flucytosine. Sex Transm Dis 2003; 79 262-266.
67. Kojic EM, Darouiche RO. Candida infections of medical devices. Clin Microbiol Rev 2004; 17: 255-267.
68. Cornely OA, Ullman AJ, Karthaus M. Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies. Blood 2003; 101: 3365-3372.
69. Segal E, Vardinon N, Foldes J, et al. Serum anti- Candida albicans antibodies in candidal and non-candidal vaginitis. Zbl Bakt Hyg 1977; 239: 548-553.
70. Mathur S, Koistinen J, Kyong CU, et al. Antibodies to Candida albicans in IgA-deficient humans. J Infect Dis 1977; 136: 436-438.
71. Gough PM, Warnock DW, Richardson MD, et al. IgA and IgG antibodies to Candida albicans in the vaginal tract secretions of women with or without vaginal candidosis. Sabouraudia 1984; 22 265-271.
72. Hernando FL, Cailliez JC, Trinel PA, et al. Qualitative and quantitative differences in recognition patterns of Candida albicans protein and polysaccharide antigens by human sera. J Med Vet Mycol 1993; 31: 219-226.
73. Goldman DL, Khine H, Abadi J, et al. Serological evidence for Cryptococcus neoformans infections in early childhood. Pediatrics 2001; 107: E66.
74. Jorizzo JL. Chronic mucocutaneous candidosis. Arch Dermatol 1982; 118: 963-965.
75. Farah CS, Ashman RB, Challacombe SJ. Oral candidosis. Clin Dermatol 2000; 18: 553-562.
76. Myers TA, Leigh JE, Arribas AR, et al. Immunohistochemical evaluation of T cells in oral lesions from human immunodeficiency virus-positive persons with oropharyngeal candidiasis. Infect Immun 2003; 71: 956-963.
77. Fidel PL Jr, Barousse M, Espinosa T, et al. An intravaginal live Candida challenge in humans leads to new hypotheses for the immunopathogenesis of vulvovaginal candidiasis. Infect Immun 2004; 72: 2939-2946.
78. Nucci M, Colombo AL, Spector N, et al. Breakthrough candidemia in neutropenic patients. Clin Infect Dis 1997; 24: 275-276.
79. Colovic M, Lazarevic V, Colovic R, et al. Hepatosplenic candidiasis after neutropenic phase of acute leukemia. Med Oncol 1999; 16: 139-142.
80. Han Y, Cutler JE. Assessment of a mouse model of neutropenia and the effect of an anti-candidiasis monoclonal antibody in these animals. J Infect Dis 1997; 175: 1169-1175.
81. Baghian A, Lee KW. Systemic candidosis in beige mice. J Med Vet Mycol 1989; 27: 51-55.
82. Jensen J, Warner T, Balish E. Resistance of SCID mice to Candida albicans administered intravenously or colonizing the gut: role of polymorphonuclear leukocytes and macrophages. J Infect Dis 1993; 167: 912-919.
83. Jones-Carson J, Vazquez-Torres A, Balish E. Defective killing of Candida albicans hyphae by neutrophils from beige mice. J Infect Dis 1995; 171: 1664-1667.
84. Walsh TJ, Lee JW, Lecciones J, et al. SCH-39304 in prevention and treatment of disseminated candidiasis in persistently granulocytopenic rabbits. Antimicrob Agents Chemother 1990; 34 1560-1564.
85. Walsh TJ, Aoki S, Mechinaud E et al. Effects of preventive, early, and late antifungal chemotherapy with fluconazole in different granulocytopenic models of experimental disseminated candidiasis. J Infect Dis 1990; 161: 755-760.
86. Fidel PL Jr, Sobel JD. The role of cell-mediated immunity in candidiasis. Trends Microbiol 1995; 2: 202-206.
87. Kagaya K, Shinoda T, Fukazawa Y. Murine defense mechanism against Candida albicans infection I. Collaboration of cell-mediated and humoral immunities in protection against systemic C. albicans infection. Microbiol Immunol 1981; 25: 647-654.
88. Netea MG, Van der Meer JWM, Verschueren I, et al. CD40/CD40 ligand interactions in the host defense against disseminated Candida albicans infection: the role of macrophage-derived nitric oxide. Eur J Immunol 2002; 32: 1455-1463.
89. Brawner DL, Hovan AJ. Oral candidiasis in HIV-infected patients. AIDS Reader 1992; July/August: 117-124.
90. Huang YC, Lin TY, Len HS, et al. Yeast carriage on hands of hospital personnel working in intensive care units. J Hosp Infect 1998; 39: 47-51.
91. Tollemar J, Gross N, Dolgiras N, et al. Fungal prophylaxis by reduction of fungal colonization by oral administration of bovine anti-Candida antibodies in bone marrow transplant recipients. Bone Marrow Transplant 1999; 23: 283-290.
92. Xu J, Gordon JI. Honor thy symbionts. Proc Natl Acad Sci 2003; 100: 10452-10459.
93. Dubos R, Schaedler RW, Costello R, et al. Indigenous, normal, and autochthonous flora of the gastrointestinal tract. J Exp Med 1965; 122: 67-76.
94. Katikaneni LD, Mathur S. Humoral immunity to Candida albicans (anti-Candida antibody titers) in premature infants. Am J Reprod Immunol 1990; 23: 1-3.
95. Noverr MC, Noggle RM, Toews GB, et al. Role of antibiotics and fungal microbiota in driving pulmonary allergic responses. Infect Immun 2004; 72: 4996-5003.
96. Elahi S, Clancy R, Pang G. A therapeutic vaccine for mucosal candidiasis. Vaccine 2001; 19: 2516-2521.
97. Brumuro C, Torosantucci A, Chiani P, et al. Interplay between protective and inhibitory antibodies dictates the outcome of experimentally disseminated candidiasis in recipients of Candida albicans vaccine. Infect Immun 2002; 70: 5462-5470.
98. Gregory RL. Microbial ribosomal vaccines. Rev Infect Dis 1986; 8: 208-217.
99. Segal E, Fungal ribosomal vaccines I. Histoplasma and Candida vaccines. Mycopothologia 1989; 105: 45-48.
100. Levy R, Segal E, Eylan E. Protective immunity against murine candidiasis elicited by Candida albicans ribosomal fractions. Infect Immun 1981; 31: 874-878.
101. Levy R, Segal E, Barr-Nea L. Systemic candidiasis in mice immunized with Candida albicans ribosomes. Mycopathologia 1985; 91: 17-22.
102. Segal E, Sandovsky-Losica H. Experimental vaccination with Candida albicans ribosomes in cyclophosphamide-treated animals. Sabouraudia 1981; 19: 267-273.
103. Segal E, Spungin A, Levy R, et al. Induction of protection against candidiasis in tumor-bearing mice by vaccination with Candida albicans ribosomes. J Med Vet Mycol 1987; 25: 355-363.
104. Eckstein M, Barenholz Y, Bar LK, et al. Liposomes containing Candida albicans ribosomes as a prophylactic vaccine against disseminated candidiasis in mice. Vaccine 1997; 15: 220-224.
105. Segal E, Sandovsky-Losica H, Nussbaum S. Immune responses elicited by vaccinations with Candida albicans ribosomes in cyclophosphamide treated animals. Mycopathologia 1985; 89: 113-118.
106. Kanbe T, Cutler JE. Evidence for adhesin activity in the acid-stable moiety of the phosphomannoprotein cell wall complex of Candida albicans. Infect Immun 2004; 62: 1662-1668.
107. Kanbe T, Han Y, Redgrave B, et al. Evidence that mannans of Candida albicans are responsible for adherence of yeast forms to spleen and lymph nodes. Infect Immun 1993; 61: 2578-2584.
108. Han Y, Cutler JE. Antibody response that protects against disseminated candidiasis. Infect Immun 1995; 63: 2714-2719.
109. Han Y, Morrison RP, Cutler JE. A vaccine and monoclonal antibodies that enhance mouse resistance to Candida albicans vaginal infection. Infect Immun 1998; 66: 5771-5776.
110. Han Y, Ulrich MA, Cutler JE. Candida albicans mannan extract-protein conjugates induce a protective immune response against experimental candidiasis. J. Infect Dis 1999; 179: 1477-1484.
111. Han Y, Kanbe T, Cherniak R, et al. Biochemical characterization of Candida albicans epitopes that can elicit protective and nonprotective antibodies. Infect Immun 1997; 65 4100-4107.
112. Nitz M, Ling C-C, Otter A, et al. The unique solution structure and immunochemistry of the Candida albicans β-1,2-mannopyranan cell wall antigens. J Biol Chem 2002; 277 3440-3446.
113. Bystricky S, Paulovicova E, Machova E. Candida albicans mannan-protein conjugate as vaccine candidate. Immunol Lett 2003; 85: 251-255.
114. Caesar-TonThat TC, Cutler JE. A monoclonal antibody to Candida albicans enhances mouse neutrophil candidacidal activity. Infect Immun 1997; 65: 5354-5357.
115. Han Y, Kozel TR, Zhang MX, et al. Complement is essential for protection by an IgM and an IgG3 monoclonal antibody against experimental, hematogenously disseminated candidiasis. J. Immunol 2001; 167: 1550-1557.
116. Beenhouwer DO, Shapiro S, Feldmesser M, et al. Both Th1 and Th2 cytokines affect the ability of monoclonal antibodies to protect mice against Cryptococcus neoformans. Infect Immun 2001; 69: 6445-6455.
117. Vecchiarelli A, Retini C, Monari C, et al. Specific antibody to Cryptococcus neoformans alters human leukocyte cytokine synthesis and promotes T-cell proliferation. Infect Immun 1998; 66: 1244-1247.
118. Sawant AD, Abdelal AT, Ahearn DG. Purification and characterization of the anti-Candida toxin of Pichia anomala WC 65. Antimicrob Agents Chemother 1989; 33: 48-52.
119. Matthews HL, Conti S, Witek-Janusek L, et al. Effect of Pichia anomala killer toxin on Candida albicans. Med Mycol 1998; 36: 199-204.
120. Pettoello-Mantovani M, Nocerino A, Polonelli L, et al. Hansenula anomala killer toxin induces secretion and severe acute injury in the rat intestine. Gastroenterology 1995; 109: 1900-1906.
121. Conti S, Cantelli C, Gerloni M, et al. Killer factor interference in mixed opportunistic yeast cultures. Mycopathologia 1996; 135: 1-8.
122. Polonelli L, Morace G. Production and characterization of yeast killer toxin monoclonal antibodies. J Clin Microbiol 1987; 25: 460-462.
123. Polonelli L, Morace G. Yeast killer toxin-like anti-idiotypic antibodies. J Clin Microbiol 1988; 26: 602-604.
124. Polonelli L, Lorenzini R, De Bernardis F, et al. Idiotypic vaccination: immunoprotection mediated by anti-idiotypic anti-bodies with antibiotic activity. Scand J Immunol 1993; 37 105-110.
125. Polonelli L, De Bernardis F, Conti S, et al. Idiotypic intravaginal vaccination to protect against candidal vaginitis by secretory, yeast killer toxin-like anti-idiotypic antibodies. J Immunol 1994; 152: 3175-3182.
126. Polonelli L, De Bernardis F, Conti S, et al. Human natural yeast killer toxin-like candidal antibodies. J Immunol 1996; 156: 1880-1885.
127. Jerne NK. Towards a network theory of the immune system. Ann Immunol 1974; 125C: 373-389.
128. Polonelli L, Magliani W, Conti S, et al. Therapeutic activity of an engineered synthetic killer antiidiotypic antibody fragment against experimental mucosal and systemic candidiasis. Infect Immun 2003. 71: 6205-6212.
129. Romani L. Immunity to fungal infections. Nat Rev Immunol 2004; 4: 11-24.
130. Tammock GW. Medical Importance of the Normal Microflora Dordrecht: Kluwer Academic Publishers, 1999.
131. Macpherson AJ, Gatto D, Sainsbury E, et al. A primitive T cell-independent mechanism of intestinal mucosal IgA responses to commensal bacteria. Science 2004; 288: 2222-2226.
132. Macpherson A, Khoo UY, Forgacs I, et al. Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut 1996; 38: 365-375.
133. Whelan WL, Kirsch DR, Kwon-Chung KJ, et al. Candida albicans in patients with the acquired immunodeficiency syndrome: absence of a novel or hypervirulent Strain. J Infect Dis 1990; 162: 513-518.
134. Matthews R, Burnie J. The role of hsp90 in fungal infection. Immunol Today 1992; 13: 345-348.
135. Matthews RC, Burnie JP. Recombinant antibodies: a natural partner in combinatorial antifungal therapy. Vaccine 2004; 22 865-871.
136. Matthews R, Burnie J, Smith D, et al. Candida and AIDS: evidence for protective antibody. Lancet 1988; 2: 263-266.
137. Matthews RC, Burnie JP, Howat D, et al. Autoantibody to heat-shock protein 90 can mediate protection against systemic candidosis. Immunology 1991; 74: 20-24.
138. Matthews R, Hodgetts S, Burnie J. Preliminary assessment of a human recombinant antibody fragment to hsp90 in murine invasive candidiasis. J Infect Dis 1995; 171: 1668-1671.
139. Matthews RC, Rigg G, Hodgetts S, et al. Preclinical assessment of the efficacy of Mycograb, a human recombinant antibody against fungal hsp90. Antimicrob Agents Chemother 2003; 47: 2208-2216.
140. Nooney L, Matthews R, Burnie J. Synergistic activity of Mycograb and amphotericin B against Cryptococcus neoformans (F-002). 104th ASM General Meeting, 23 May 2004, New Orleans, LA, USA.
141. Tavares D, Salvador A, Ferreira P, et al. Immunological activities of a Candida albicans protein which plays an important role in the survival of the microorganism in the host. Infect Immun 1993; 61: 1881-1888.
142. Villanova M, Tavares D, Ferreira P, et al. Role of monocytes in the up-regulation of the early activation marker CD69 on B and T murine lymphocytes induced by microbial mitogens. Scand J Immunol 1996; 43: 155-163.
143. Arala-Chaves M. Is prophylactic immunostimulation of the host against pathogenic microbial antigens an adequate strategy of immunoprotection. Scand J Immunol 1992; 35: 495-500.
144. Tavares D, Ferreira P, Arala-Chaves M. Increased resistance to systemic candidiasis in athymic or interleukin-10-depleted mice. J Infect Dis 2000; 182: 266-273.
145. Tavares D, Ferreira P, Vilanova M, et al. Immunoprotection against systemic candidiasis in mice. Int Immunol 1995; 7: 785-796.
146. Tavares D, Ferreira P, Arala-Chaves M. Increased resistance in BALB/c mice to reinfection with Candida albicans is due to immunoneutralization of a virulence-associated immunomodulatory protein. Microbiology 2003; 149: 333-339.
147. Vecchiarelli A, Mazzolla R, Farinelli S, et al. Immunomodulation by Candida albicans: crucial role of organ colonization and chronic infection with an attenuated agerminative strain of C. albicans for establishment of anti-infectious protection. J Gen Microbiol 1988; 134: 2583-2592.
148. Staab JF, Bradway SD, Fidel PL, et al. Adhesive and mammalian transglutaminase substrate properties Candida albicans Hwp1. Science 1999; 283: 1535-1538.
149. Klotz SA, Gaur NK, Lake DF, et al. Degenerate peptide recognition by Candida albicans adhesins Als5p and Als 1 p. Infect Immun 2004; 72: 2029-2034.
150. Sheppard DC, Yeaman MR, Welch WH, et al. Functional and structural diversity in the Als protein family of Candida albicans. J Biol Chem 2004; 279: 30480-30489.
151. Sundstrom P. Adhesion in Candida spp. Cell Microbiol 2002; 4: 461-469.
152. Schaller M, Bein M, Korting HC, et al. The secreted aspartyl proteinases Sap1 and Sap2 cause tissue damage in an in vitro model of vaginal candidiasis based on reconstituted human vaginal epithelium. Infect Immun 2003; 71: 3227-3234.
153. Naglik JR, Rodgers CA, Shirlaw PJ, et al. Differential expression of Candida albicans secreted aspartyl proteinase and phospholipase B genes in humans correlates with active oral and vaginal infection. J Infect Dis 2003; 188: 469-479.